Bannink Ellen M N, van Doorn Jaap, Mulder Paul G H, Hokken-Koelega Anita C S
Erasmus MC-Sophia Children's Hospital, Department of Pediatrics, Dr. Molewaterplein 60, 3015 GJ Rotterdam, The Netherlands.
J Clin Endocrinol Metab. 2007 Aug;92(8):2992-3000. doi: 10.1210/jc.2006-0677. Epub 2007 May 15.
IGF-I plays an important role in pre- and postnatal growth. Its serum levels are regulated by metabolic and genetic factors. Mean total IGF-I in short, small for gestational age (SGA) children is reduced, but within the normal range. Free/dissociable IGF-I is the bioactive form of IGF-I.
The aim of the study was to investigate changes in free IGF-I during GH treatment in short SGA children and to evaluate whether free IGF-I levels contribute to predicting first-year growth response and/or adult height. DESIGN, SETTING, AND INTERVENTION: We conducted a randomized, double-blind GH dose-response study with a GH dose of either 1 mg/m(2).d (group A) or 2 mg/m(2).d (group B). Free IGF-I, total IGF-I, and IGF binding protein (IGFBP)-3 were determined at baseline, after 1 and 5 yr, at stop, and 6 months after GH discontinuation.
We studied 73 (46 male) short SGA children (36 group A) with a baseline mean age of 7.7 (2.2) yr and a mean GH duration of 8.2 (2.1) yr.
Untreated SGA children had a mean free IGF-I sd score (SDS) of -0.2 (1.2), not related to total IGF-I. During GH therapy, free IGF-I significantly increased to 1.6 (0.7) SDS, as did total IGF-I and IGFBP-3 [2.0 (0.8) and 1.3 (0.9), respectively]. Multiple regression analysis showed that baseline free IGF-I and IGFBP-3 were negatively correlated with adult height SDS, whereas baseline bone age delay, target height SDS, baseline height SDS, and GH dose were positively correlated. Free IGF-I was also negatively correlated with first-year growth response.
Circulating baseline free IGF-I and IGFBP-3 were better predictors for adult height in GH-treated SGA children than total IGF-I, or total IGF-I to IGFBP-3 ratio. This suggests a possible role for free IGF-I measurement in predicting the effect of GH therapy in short SGA children.
胰岛素样生长因子-I(IGF-I)在出生前和出生后的生长过程中发挥着重要作用。其血清水平受代谢和遗传因素调节。身材矮小、小于胎龄(SGA)儿童的平均总IGF-I水平降低,但仍在正常范围内。游离/可解离IGF-I是IGF-I的生物活性形式。
本研究旨在调查矮小SGA儿童生长激素(GH)治疗期间游离IGF-I的变化,并评估游离IGF-I水平是否有助于预测第一年的生长反应和/或成人身高。设计、地点和干预措施:我们进行了一项随机、双盲的GH剂量反应研究,GH剂量为1mg/m²·d(A组)或2mg/m²·d(B组)。在基线、治疗1年和5年后、停药时以及停药后6个月测定游离IGF-I、总IGF-I和IGF结合蛋白(IGFBP)-3。
我们研究了73名(46名男性)矮小SGA儿童(36名A组)基线平均年龄为7.7(2.2)岁,平均GH治疗时间为8.2(2.1)年。
未经治疗的SGA儿童游离IGF-I标准差评分(SDS)平均为-0.2(1.2),与总IGF-I无关。在GH治疗期间,游离IGF-I显著增加至1.6(0.7)SDS,总IGF-I和IGFBP-3也显著增加[分别为2.0(0.8)和1.3(0.9)]。多元回归分析显示,基线游离IGF-I和IGFBP-3与成人身高SDS呈负相关,而基线骨龄延迟、靶身高SDS、基线身高SDS和GH剂量呈正相关。游离IGF-I与第一年生长反应也呈负相关。
对于接受GH治疗的SGA儿童,循环基线游离IGF-I和IGFBP-3比总IGF-I或总IGF-I与IGFBP-3的比值更能预测成人身高。这表明游离IGF-I检测在预测矮小SGA儿童GH治疗效果方面可能具有一定作用。